Company Bio-Bridge Science Inc.

Bio-Bridge Science, Inc. (Bio-Bridge) is a biotech company focused on the commercial development of biological products for the prevention and treatment of human diseases and manufacturing and sales of materials in producing vaccines. It focuses on developing and obtaining regulatory approval for commercial sale of vaccines, such as a human immunodeficiency virus (HIV) vaccine (HIV-PV Vaccine I), a vaccine designed to prevent and treat infection by the HIV, an HPV vaccine, a colon cancer therapeutic vaccine and other related potential products. Bio-Bridge produces and sells bovine serum, a major production material in producing vaccines, through its 51% owned subsidiary, Bio-Bridge XHBD. The Company has finished the pre-clinical animal testing of HIV-PV Vaccine I through collaboration with Beijing Institute of Radiation Medicine. The Company’s colon cancer vaccine is a Papillomavirus Pseudovirus containing a plasmid encoding carcinoembryonic antigen (CEA) that is to be given orally.